Finally, ADAM17 selective inhibitors significantly reduced CRC metastasis in vivo; therefore, these ADAM17 inhibitors are promising therapeutic candidates for further development, holding the potential to effectively inhibit CRC metastasis in clinical practice. The gene discussed is ADAM17; the disease is colorectal carcinoma.